
    
      The primary objective is to evaluate the analgesic efficacy of intravenous (IV) TRV130
      administered via patient controlled analgesia device (PCA) compared with placebo administered
      via PCA in patients with moderate to severe, acute postoperative pain following
      abdominoplasty.
    
  